戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 of invasive aspergillosis, mucormycosis, and Pneumocystis pneumonia.
2  COVID-19, community-acquired pneumonia, and Pneumocystis pneumonia.
3 phages during infection using a rat model of Pneumocystis pneumonia.
4 e in the respiratory failure associated with Pneumocystis pneumonia.
5 major cause of respiratory impairment during Pneumocystis pneumonia.
6 umber of case reports of patients developing Pneumocystis pneumonia.
7 uate risk factors associated with late-onset Pneumocystis pneumonia.
8 d antibody responses before and after active Pneumocystis pneumonia.
9 ely contributes to the effect of nicotine on Pneumocystis pneumonia.
10 onic nicotine infusion blocks development of Pneumocystis pneumonia.
11 bility to an opportunistic infection such as Pneumocystis pneumonia.
12 rther promoting lung inflammation typical of Pneumocystis pneumonia.
13 odeficiency virus (HIV)-infected adults with Pneumocystis pneumonia.
14 pportunistic infections in these patients is Pneumocystis pneumonia.
15 ctions, including malaria, toxoplasmosis and Pneumocystis pneumonia.
16 uency of interstitial lung disease mimicking Pneumocystis pneumonia.
17 lating proinflammatory signaling pathways in Pneumocystis pneumonia.
18 for patients with HIV and moderate to severe Pneumocystis pneumonia (13% vs 25%).
19  the most frequently diagnosed AIDS-OIs were Pneumocystis pneumonia (39.1%) and Kaposi sarcoma (20.1%
20   W3/25 also did not enhance the severity of Pneumocystis pneumonia achieved with corticosteroids alo
21 ose IL-2 therapy, two patients who developed Pneumocystis pneumonia and one patient who developed an
22  but they are less likely to be admitted for Pneumocystis pneumonia and other HIV-associated opportun
23 losis, and was largest for oral candidiasis, Pneumocystis pneumonia, and toxoplasmosis.
24 lung in CD4-deficient humans and mice during Pneumocystis pneumonia, and we have found that these CD8
25 community-acquired pneumonia, influenza, and Pneumocystis pneumonia, are a leading cause of death amo
26 r adjustment for known confounders and using Pneumocystis pneumonia as the referent category, mortali
27 monstrate a role for NK cells in immunity to Pneumocystis pneumonia, as well as to establish a functi
28 ar tools for early and accurate diagnosis of Pneumocystis pneumonia, aspergillosis, candidemia, and e
29 plays a central role in host defense against Pneumocystis pneumonia but has received only limited att
30  and used to help manage the pathogenesis of Pneumocystis pneumonia by adoptive transfer.
31  KEX1-immunized macaques were protected from Pneumocystis pneumonia, compared with mock-immunized ani
32                                              Pneumocystis pneumonia continues to carry significant ma
33                       CD4-depleted mice with Pneumocystis pneumonia demonstrated significant mortalit
34 ents who developed and recovered from active Pneumocystis pneumonia during the study exhibited an inc
35  bacterial pneumonia, and moderate to severe Pneumocystis pneumonia (for patients with HIV).
36                          Previous episode of Pneumocystis pneumonia, geographic location, and age wer
37                       Patients who died from Pneumocystis pneumonia had higher levels of antibody to
38                   In the era of prophylaxis, Pneumocystis pneumonia has become a late-onset opportuni
39 reased mortality of patients with malaria or Pneumocystis pneumonia has been linked to the appearance
40                                              Pneumocystis pneumonia has dramatic consequences in kidn
41                                              Pneumocystis pneumonia has dramatic consequences in kidn
42                                              Pneumocystis pneumonia has long been recognized as a cau
43 P may be the most common diagnosis mimicking Pneumocystis pneumonia in acquired immune deficiency syn
44  of this treatment to prevent mortality from pneumocystis pneumonia in adults living with HIV.
45 herapeutic effect in the treatment of murine Pneumocystis pneumonia in CD4-depleted mice.
46 cluding Pneumocystis jirovecii, which causes Pneumocystis pneumonia in humans, Pneumocystis carinii,
47 and provide insights into the development of Pneumocystis pneumonia in immunodeficient hosts.
48  therapeutic development in the treatment of Pneumocystis pneumonia in the immunosuppressed populatio
49 alities from opportunistic diseases, such as Pneumocystis pneumonia, in AIDS patients.
50                                              Pneumocystis pneumonia is a life-threatening opportunist
51                                              Pneumocystis pneumonia is a major cause of morbidity and
52                                              Pneumocystis pneumonia is a well-recognized lung disease
53                   Respiratory failure during Pneumocystis pneumonia is mainly a consequence of exagge
54  indicate that downregulation of PU.1 during Pneumocystis pneumonia leads to decreased expression of
55                             We conclude that Pneumocystis pneumonia leads to increased mortality foll
56                                              Pneumocystis pneumonia occurred at a median of 3 years a
57 very rare, with about 30 cases per year, and Pneumocystis pneumonia occurs in 53-959 patients annuall
58                                Patients with Pneumocystis pneumonia often develop respiratory failure
59 le of the cytokine interleukin-12 (IL-12) in Pneumocystis pneumonia or its potential use as immunothe
60 6 kg/m(2), P = .03), history of bacterial or Pneumocystis pneumonia (P = .01), and not currently taki
61 ded mean antibody levels by status at death (Pneumocystis pneumonia, P. jirovecii colonization, or ne
62 n numerous reports of clustered outbreaks of Pneumocystis pneumonia (PCP) at renal transplant centers
63                                              Pneumocystis pneumonia (PCP) caused by Pneumocystis jiro
64 h chronic lymphocytic leukemia who died from Pneumocystis pneumonia (PCP) despite appropriate anti-Pn
65                   In the era of prophylaxis, Pneumocystis pneumonia (PCP) has become a late-onset opp
66 T cells contribute to the pathophysiology of Pneumocystis pneumonia (PcP) in a murine model of AIDS-r
67  smoking correlates with reduced episodes of Pneumocystis pneumonia (PCP) in AIDS patients, we tested
68 es obtained during 113 episodes of suspected Pneumocystis pneumonia (PCP) in human immunodeficiency v
69 vecii is an opportunistic fungus that causes Pneumocystis pneumonia (PCP) in immunocompromised hosts.
70 ocystis spp. are yeast-like fungi that cause pneumocystis pneumonia (PcP) in immunocompromised indivi
71 e, risk factors, morbidity, and mortality of Pneumocystis pneumonia (PCP) in recipients of kidney tra
72                               Development of Pneumocystis pneumonia (PCP) is a common problem among i
73                                              Pneumocystis pneumonia (PcP) is a life-threatening infec
74                                              Pneumocystis pneumonia (PCP) is a major cause of morbidi
75                                              Pneumocystis pneumonia (PCP) is a potentially lethal opp
76                                              Pneumocystis pneumonia (PCP) is associated with morbidit
77                                              Pneumocystis pneumonia (PcP) is the most common opportun
78                                              Pneumocystis pneumonia (PcP) is the second leading cause
79 investigated whether primary prophylaxis for pneumocystis pneumonia (PcP) might be withheld in all pa
80 se chain reaction (PCR) for the diagnosis of Pneumocystis pneumonia (PCP) on different respiratory tr
81 4; by ELISA, immunocompromised patients with Pneumocystis pneumonia (PCP) who were immunocompromised
82 i) is important in the immunopathogenesis of Pneumocystis pneumonia (PcP), but is difficult to study
83  of alveolar macrophages is decreased during Pneumocystis pneumonia (Pcp), partly because of activati
84                                              Pneumocystis pneumonia (PCP), the most common opportunis
85               In the mouse and rat models of Pneumocystis pneumonia (PcP), we found a distinct popula
86 tis infection but is also a key component of Pneumocystis pneumonia (PcP)-related immunopathogenesis.
87 esponse protects healthy individuals against Pneumocystis pneumonia (PcP).
88 ntly found to accumulate in the lungs during Pneumocystis pneumonia (PcP).
89 d lead to improved strategies for preventing Pneumocystis pneumonia (PCP).
90  mRNA levels were also reduced in Amo during Pneumocystis pneumonia (Pcp).
91 ges is decreased in patients or animals with Pneumocystis pneumonia (Pcp).
92 ly used to guide the management of suspected Pneumocystis pneumonia (PCP).
93  3 most common OIs among study patients were Pneumocystis pneumonia (PCP, 28%), Candida esophagitis (
94 atory fungal pathogen that causes pneumonia (Pneumocystis pneumonia [PcP]) in immunocompromised patie
95  isolates from the 18 RTRs (12 patients with Pneumocystis pneumonia [PCP], 6 colonized patients), 22
96 oxazole is considered first-line therapy for Pneumocystis pneumonia prevention in renal transplant re
97 essful in improving the uptake of first-line Pneumocystis pneumonia prophylaxis in renal transplant r
98 rospectively reviewed 119 patients receiving Pneumocystis pneumonia prophylaxis prior to and after pr
99                                              Pneumocystis pneumonia prophylaxis should be considered
100                              Failure to take Pneumocystis pneumonia prophylaxis was associated with h
101 e older age, history of bacterial pneumonia, Pneumocystis pneumonia, pulmonary tuberculosis and immun
102 N-gamma demonstrated an initial worsening of Pneumocystis pneumonia-related immunopathogenesis, with
103 n the immunopathogenic mechanisms underlying Pneumocystis pneumonia-related lung injury and examine t
104                                              Pneumocystis pneumonia remains a common opportunistic in
105 a predisposing factor for the development of Pneumocystis pneumonia, specific Th mechanisms mediating
106 hniques, we demonstrated in a mouse model of Pneumocystis pneumonia that treatment with caspofungin,
107 8 T-cells are implicated in the pathology of Pneumocystis pneumonia, they did not have a role in the
108                                              Pneumocystis pneumonia was associated with high incidenc
109                                              Pneumocystis pneumonia was first diagnosed in malnourish
110                    Using our murine model of Pneumocystis pneumonia, we found that loss of NK cells d
111  virus (HIV)-positive patients with presumed Pneumocystis pneumonia were analyzed to determine the sp
112 he covariables independently associated with Pneumocystis pneumonia were the total lymphocyte count o
113 ingitis and Legionella, cytomegalovirus, and Pneumocystis pneumonias), which occurred up to 7 months
114  on the health of the rats and the levels of Pneumocystis pneumonia, which were milder than those fou
115                  Prevention and treatment of Pneumocystis pneumonia with trimethoprim/sulfamethoxazol

 
Page Top